Gilead Sciences has made another foray into the natural killer (NK) cell category, paying $300 million upfront to access Dragonfly Therapeutics' TriNKET platform to find therapies for cancer and ...
Bristol-Myers Squibb has signed an agreement worth $475 million to develop a new form of cancer immunotherapy drug with US biotech Dragonfly Therapeutics. BMS is best known as an early pioneer of ...
About Dragonfly Energy Holdings Corp. Dragonfly Energy Holdings Corp. engages in the manufacture and supply of deep cycle lithium-ion batteries. It also focuses on delivering an energy storage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback